John Huber
Family · Morgantown, WVNPI 1649521758
Payments from drug & device makers
Across 687 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$2K
- Novo Nordisk$972
- Lilly USA, LLC$935
- Pfizer$662
- Novartis$400
- plus $4K from 30 others
What the payments were for
- Consulting fees$4003%
- Food & beverage$11,14296%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 201 | $2,608 |
| AstraZeneca | 57 | $1,823 |
| Novo Nordisk | 49 | $972 |
| Lilly USA, LLC | 62 | $935 |
| Pfizer | 41 | $662 |
| Novartis | 34 | $400 |
| Exact Sciences | 20 | $382 |
| Astellas Pharma US Inc | 21 | $375 |
| Boehringer Ingelheim | 19 | $313 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $300 |
| Sanofi-aventis U.S. LLC | 23 | $299 |
| Amgen | 25 | $297 |
| Bayer | 18 | $295 |
| Shield Therapeutics Inc | 9 | $234 |
| GSK | 15 | $228 |
| Phathom Pharmaceuticals, Inc. | 10 | $194 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Abbott | 7 | $117 |
| Dexcom, Inc. | 7 | $103 |
| Azurity Pharmaceuticals, Inc. | 5 | $92 |
| Sunovion Pharmaceuticals Inc. | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $77 |
| Insulet Corporation | 4 | $76 |
| Esperion Therapeutics, Inc. | 4 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Mylan Specialty L.p. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Eisai Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Amarin Pharma, Inc. | 3 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Merck | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,549 in reported general payments places this provider in the 95th percentile of 1,507 family providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 84 | $119,380 |
| EliquisApixaban | 100 | $110,708 |
| JardianceEmpagliflozin | 90 | $110,637 |
| OzempicSemaglutide | 81 | $104,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $104,105 |
| TrulicityDulaglutide | 47 | $85,815 |
| FarxigaDapagliflozin Propanediol | 62 | $75,187 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $51,243 |
| JanuviaSitagliptin Phosphate | 29 | $39,828 |
| LinzessLinaclotide | 36 | $36,490 |
| EntrestoSacubitril/Valsartan | 20 | $28,527 |
| XareltoRivaroxaban | 22 | $23,362 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $22,612 |
| Repatha SureclickEvolocumab | 13 | $20,873 |
| KeppraLevetiracetam | 12 | $18,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $935 | $205,195131 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $228 | $114,53293 claims |
| PfizerEliquis | $662 | $110,708100 claims |
| Boehringer IngelheimJardiance | $313 | $110,63790 claims |
| Novo NordiskOzempic | $972 | $104,40281 claims |
| AstraZenecaFarxiga, Symbicort | $1,823 | $82,73777 claims |
| MerckJanuvia | $35 | $39,82829 claims |
| AbbVieLinzess | $2,608 | $36,49036 claims |
| NovartisEntresto | $400 | $28,52720 claims |
| Johnson & JohnsonXarelto | $38 | $23,36222 claims |
| Astellas Pharma US IncMyrbetriq | $375 | $17,95739 claims |
| BayerKerendia | $295 | $17,52419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,507 family providers in West Virginia.
Other family in Morgantown
- Justin HayesMorgantown$12K
- Peggy FergusonMorgantown$9K
- Samantha KingMorgantown$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.